Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement safety shift of onus to industry counters DSHEA, Amway tells commission.

This article was originally published in The Tan Sheet

Executive Summary

SUPPLEMENT SAFETY BURDEN OF PROOF SHIFT TO INDUSTRY COUNTERS DSHEA, AMWAY maintains in July 24 comments on the President's Commission on Dietary Supplement Labels draft report. The draft report on dietary supplement labeling and claims issues was released June 24; the comment period on the draft ends Aug. 4 ("The Tan Sheet" June 30, pp. 17-25). The draft report states that "the industry as a whole must fully accept the responsibility for assuring the safety of dietary supplements." Amway's Nutrilite Division responds, however, that "the shifting of onus inherent in this presentation back to industry is counter to the letter of [the Dietary Supplement Health & Education Act]....This recommendation from the commission serves the function of altering the letter of the statute."

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel